Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial
Authors:
- Parvin TajikPTParvin Tajik
- Michel H.P. HofMHMichel H.P. Hof
- Ignace VergoteIVIgnace Vergote
- Gemma G. KenterGKGemma G. Kenter
- Ben Willem J. MolBMBen Willem J. Mol
- Marrije R. BuistMBMarrije R. Buist
- Patrick M. BossuytPBPatrick M. Bossuyt
- 1 October 2013
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 49 (15) , 3191-3201
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?Gynecologic Oncology, 2013
- Is the Easier Way Ever the Better Way?Journal of Clinical Oncology, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experienceCancer, 2010
- 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)Annals of Oncology, 2005
- Identification of Prognostic Factors in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 2001
- Ovarian cancer: Epidemiology, biology, and prognostic factorsSeminars in Surgical Oncology, 2000
- Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trialsBritish Journal of Cancer, 1995
- Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.Journal of Clinical Oncology, 1991
- Prognostic factors in advanced epithelial ovarian cancerBritish Journal of Cancer, 1990